Pazopanib-Induced Asymptomatic Necrotizing Pancreatitis Diagnosed on (18)F-FDG PET-CT Scan

Multi-targeted tyrosine kinase inhibitor (TKI) pazopanib approved for the treatment of advanced soft tissue sarcoma (STS) has prolonged the estimated survival times and quality of life of patients. However, several adverse effects associated predominantly with the inhibition of the vascular endothel...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Melvika, Shivdasani, Divya, Singh, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771063/
https://www.ncbi.nlm.nih.gov/pubmed/35125763
http://dx.doi.org/10.4103/ijnm.ijnm_49_21
Descripción
Sumario:Multi-targeted tyrosine kinase inhibitor (TKI) pazopanib approved for the treatment of advanced soft tissue sarcoma (STS) has prolonged the estimated survival times and quality of life of patients. However, several adverse effects associated predominantly with the inhibition of the vascular endothelial growth factor receptor by these drugs may prove to be potentially life-threatening. One such rare adverse event with the use of pazopanib is acute pancreatitis. We present a case of asymptomatic necrotizing pancreatitis induced by pazopanib treatment for metastatic STS detected on (18)F-FDG PET-CT imaging.

Ejemplares similares